Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis
- Shanshan Liu
- Bi Yin
- Bo Wu
- Zhixing Fan
Affiliations: Department of Physical Examination, 904th Hospital of Joint Logistic Support Force of PLA, Wuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu 214000, P.R. China, Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang, Hubei 443000, P.R. China
- Published online on: April 21, 2022 https://doi.org/10.3892/etm.2022.11333
Copyright: © Liu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
To evaluate the effects and safety of sacubitril/valsartan in patients with acute myocardial infarction (AMI), a total of four databases, including PubMed, Cochrane Library, Embase and Web of Science, and the ClinicalTrials.gov website were searched. Using a combination of medical subject headings and entry terms, the final search was performed in July 2021. A manual search of cross‑references from the original articles was also conducted. The meta‑analysis was subsequently performed with Revman 5.3 software and a total of four studies comprising 586 patients were included. The results disclosed a significant reduction in major adverse cardiovascular and cerebrovascular events (MACCEs) [odds ratio (OR), 0.47; 95% confidence interval (CI), 0.30‑0.73; P=0.0007], readmission (OR, 0.45; 95% CI, 0.29‑0.71; P=0.0006), incidence of acute heart failure (AHF) (OR, 0.45; 95% CI, 0.28‑0.71; P=0.0007) and N‑terminal pro B‑type natriuretic peptide [standardized mean difference (SMD), ‑0.88; 95% CI, ‑1.55‑(‑0.21); P=0.01] in the sacubitril/valsartan group compared with that in the control group, and a random effects model was used to pool these data. No significant differences were identified in the incidence of hypotension (OR, 2.91; 95% CI, 0.55‑15.51; P=0.21), adverse events (OR, 2.19; 95% CI, 0.42‑11.37; P=0.35), left ventricular ejection fraction (mean difference, 1.96; 95% CI, ‑0.84‑4.76; P=0.17) or soluble suppression of tumorigenesis‑2 (SMD, ‑0.45; 95% CI, ‑1.62‑0.71; P=0.45) according to the random effects model.In conclusion, the present meta‑analysis revealed that sacubitril/valsartan was able to effectively reduce the incidence of MACCEs, readmission and AHF in patients with AMI after revascularization without any obvious adverse events.